Aurora Cannabis Inc. (ACB.TO)
| Previous Close | 3.9600 |
| Open | 3.8900 |
| Bid | 3.7500 x 0 |
| Ask | 3.7600 x 0 |
| Day's Range | 3.7100 - 3.9900 |
| 52 Week Range | 2.8700 - 12.8800 |
| Volume | |
| Avg. Volume | 1,910,343 |
| Market Cap | 848.221M |
| Beta (5Y Monthly) | 3.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9430 |
| Earnings Date | May 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.66 |
- CNW Group
Aurora Strengthens Leadership Position in Germany with EU-GMP Certification at Preeminent Local Cannabis Production Facility
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the company has received EU-GMP certification for its state-of-the-art medical cannabis production facility in Germany. As a leading manufacturer of medical cannabis worldwide, achieving EU-GMP certification of the company's first German manufacturing site marks a significant milestone in the fulfillment of an awarded tender by the German
- Motley Fool
These 3 Former High-Flying Stocks Can Soar Up to 439%, According to Wall Street
No matter your level of experience investing money on Wall Street, it's been a rough year. Meanwhile, the technology-driven Nasdaq Composite declined close to 30% from its November all-time high, firmly placing it in a bear market. This is why Wall Street analysts typically have a bullish outlook on many of the companies they cover.
- Motley Fool
Why Aurora Cannabis, Canopy, and Sundial Stocks Popped on Friday
Canadian cannabis company Aurora Cannabis (NASDAQ: ACB) reported its fiscal third-quarter 2022 earnings last night, and in so doing, sparked a rally across the cannabis sector today. As of 1 p.m. ET, shares of Aurora Cannabis itself are already up 13%, and peer producers Canopy Growth (NASDAQ: CGC) and Sundial Growers (NASDAQ: SNDL) are benefiting as well -- up 8.5% and 5.9%, respectively. Heading into Q3, analysts had forecast that Aurora Cannabis would lose $0.19 per share (0.25 Canadian dollars, and furthermore, this was a pro forma prediction) on sales of $41.5 million -- about CA$53.7 million.
